These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 33985966)

  • 1. Effectiveness of England's initial vaccine roll out.
    Lisewski AM
    BMJ; 2021 May; 373():n1201. PubMed ID: 33985966
    [No Abstract]   [Full Text] [Related]  

  • 2. Why England's COVID 'freedom day' alarms researchers.
    Ball P
    Nature; 2021 Jul; 595(7868):479-480. PubMed ID: 34262196
    [No Abstract]   [Full Text] [Related]  

  • 3. The primary care response to COVID-19 in England's National Health Service.
    Majeed A; Maile EJ; Bindman AB
    J R Soc Med; 2020 Jun; 113(6):208-210. PubMed ID: 32521196
    [No Abstract]   [Full Text] [Related]  

  • 4. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. England's PPE procurement failures must never happen again.
    McKee M
    BMJ; 2020 Jul; 370():m2858. PubMed ID: 32680840
    [No Abstract]   [Full Text] [Related]  

  • 6. Fixing England's COVID-19 response: learning from international experience.
    Crozier A; Mckee M; Rajan S
    J R Soc Med; 2020 Nov; 113(11):422-427. PubMed ID: 33058751
    [No Abstract]   [Full Text] [Related]  

  • 7. Reduced prescription tacrolimus use: a cross-sectional analysis of England's national prescription statistics during the COVID-19 pandemic, by region.
    Barrett R
    Kidney Int; 2020 Sep; 98(3):778-779. PubMed ID: 32593542
    [No Abstract]   [Full Text] [Related]  

  • 8. Long COVID in general practice: an analysis of the equity of NHS England's enhanced service specification.
    Hutchinson J; Checkland K; Munford L; Khavandi S; Sutton M
    Br J Gen Pract; 2022 Feb; 72(715):85-86. PubMed ID: 35091414
    [No Abstract]   [Full Text] [Related]  

  • 9. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.
    Lambert PH; Ambrosino DM; Andersen SR; Baric RS; Black SB; Chen RT; Dekker CL; Didierlaurent AM; Graham BS; Martin SD; Molrine DC; Perlman S; Picard-Fraser PA; Pollard AJ; Qin C; Subbarao K; Cramer JP
    Vaccine; 2020 Jun; 38(31):4783-4791. PubMed ID: 32507409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Infodemic and misinformation. What do we know about the effectiveness and the efficacy of the vaccine against / for SARS-CoV-2 / COVID?].
    De Vito EL; Catalano HN
    Medicina (B Aires); 2020; 80 Suppl 6():107-109. PubMed ID: 33481742
    [No Abstract]   [Full Text] [Related]  

  • 11. Targets and strategies for vaccine development against SARS-CoV-2.
    Malik JA; Mulla AH; Farooqi T; Pottoo FH; Anwar S; Rengasamy KRR
    Biomed Pharmacother; 2021 May; 137():111254. PubMed ID: 33550049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [SARS-CoV-2 vaccines].
    Benfield TL; Helweg-Larsen J
    Ugeskr Laeger; 2021 Mar; 183(10):. PubMed ID: 33734065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COVID-19 vaccines: resolving deployment challenges.
    Bull World Health Organ; 2021 Mar; 99(3):174-175. PubMed ID: 33716338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid roll out of SARS-CoV-2 antibody testing-a concern.
    Andersson M; Low N; French N; Greenhalgh T; Jeffery K; Brent A; Ball J; Pollock A; McCoy D; Iturriza-Gomara M; Buchan I; Salisbury H; Pillay D; Irving W
    BMJ; 2020 Jun; 369():m2420. PubMed ID: 32580928
    [No Abstract]   [Full Text] [Related]  

  • 15. COVID-19 vaccination: Recommendations for management of patients with allergy or immune-based diseases.
    Peter J
    S Afr Med J; 2021 Feb; 111(4):291-294. PubMed ID: 33944757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Development and use of vaccines from the 18th century to the SARS-CoV 2 period].
    Skinhøj P; Bygbjerg IC
    Ugeskr Laeger; 2021 Mar; 183(11):. PubMed ID: 33734072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early Covid-19 vaccination rollout: a commentary from England.
    Sim F
    Isr J Health Policy Res; 2021 Feb; 10(1):18. PubMed ID: 33637133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Vaccination against SARS-CoV-2 in patients with multiple sclerosis].
    Costa Frossard-França L; García-Domínguez JM; Moreno-Torres I; Fortún J; Villar LM; Meca-Lallana V
    Rev Neurol; 2021 Apr; 72(7):250-260. PubMed ID: 33764494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates.
    Ura T; Yamashita A; Mizuki N; Okuda K; Shimada M
    Vaccine; 2021 Jan; 39(2):197-201. PubMed ID: 33279318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [COVID-19 vaccines: vaccine targets, immunogenicity and allergic reactions].
    Fallet B; Miauton A; Comte D; Ribi C; Muller YD
    Rev Med Suisse; 2021 Apr; 17(733):690-696. PubMed ID: 33830701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.